



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

SEP 25 2002

TECH CENTER 1600/2900

28/E
M.Q.J
9/26/02

Atty. Docket: FRIDKIN=1

In re Application of:) Conf. No.: 3626
Matityahu FRIDKIN, et al)
Appln. No.: 09/117,380) Art Unit: 1652
Filed: January 27, 1999) Examiner: R. Hutson
For: ANTI-INFLAMMATORY PEPTIDES) September 23, 2002
DERIVED FROM C-REACTIVE)
PROTEIN)

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of July 8, 2002,
please amend as follows:

IN THE CLAIMS

Delete claims 14 and 15 and insert therefor new 25
as follows:

25 (New). An isolated peptide capable of inhibiting
in vitro the enzymatic activity of human Leukocyte Elastase
(hLE) and/or of human Cathepsin G (hCG), said peptide being:

(A) a core peptide identical to positions 89-96 of
the sequence of human C-reactive protein (CRP) of the formula:

Val₈₉-Thr-Val-Ala-Pro-Val-His-Ile₉₆ (SEQ ID NO:3);

(B) a modification of (A) in which one or more of
the following additional modifications is optionally made:

1652

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: FRIDKIN et al.

Application No.: 09/117,380

Filed: January 27, 1999

For: ANTI-INFLAMMATORY PEPTIDES DERIVED FROM C-REACTIVE PROTEIN



Art Unit: 1652

3626 Examiner: R. Hutson

Washington, D.C.

Atty.'s Docket: FRIDKIN=1

Date: September 23, 2002

RECEIVED

SEP 25 2002

TECH CENTER 1600/2900

THE COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Sir:

Transmitted herewith is an [X] Amendment []
in the above-identified application.

[XX] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

[XX] No additional fee is required.

[] The fee has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT	(Col. 2) MINUS	(Col. 3) HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	* 11	MINUS	** 20	0
INDEP.	* 1	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

SMALL ENTITY		OTHER THAN SMALL ENTITY	
RATE	ADDITIONAL FEE	RATE	ADDITIONAL FEE
x 9	\$	x 18	\$
x 42	\$	x 84	\$
+ 140	\$	+ 280	\$
ADDITIONAL FEE TOTAL		TOTAL	

- * If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- ** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.
- *** If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

[] It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

Small Entity

Response Filed Within

[] First	- \$ 55.00
[] Second	- \$ 200.00
[] Third	- \$ 460.00
[] Fourth	- \$ 720.00

Month After Time Period Set

Other Than Small Entity

Response Filed Within

[] First	- \$ 110.00
[] Second	- \$ 400.00
[] Third	- \$ 920.00
[] Fourth	- \$ 1440.00

Month After Time Period Set

[] Less fees (\$_____) already paid for ____ month(s) extension of time on _____.

[] Please charge my Deposit Account No. 02-4035 in the amount of \$_____.

[] Credit Card Payment Form, PTO-2038, is attached, authorizing payment in the amount of \$_____.

[] A check in the amount of \$_____ is attached (check no.).

[XX] The Commissioner is hereby authorized and requested to charge any additional fees which may be required in connection with this application or credit any overpayment to Deposit Account No. 02-4035. This authorization and request is not limited to payment of all fees associated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK, P.L.L.C.

Attorneys for Applicant(s)

By:

Roger L. Browdy
Registration No. 25,618

Facsimile: (202) 737-3528
Telephone: (202) 628-5197